EPISODE · Nov 13, 2024 · 40 MIN
Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI
from Founded & Funded · host Madrona
What does it take to move from cutting-edge academic research to launching a biotech company that could transform medicine? In this week's episode of Founded & Funded, Madrona Partner Chris Picardo sat down with Jamie Lazarovitz, CEO and co-founder of Archon Biosciences, to uncover the story behind their groundbreaking protein-based biologics and their unique Antibody Cages (AbCs). From bootstrapping deep tech investments as a student to navigating the challenges of commercializing revolutionary science, Jamie shares the pivotal moments, tough decisions, and key lessons that led to Archon's creation. This isn't just a story for biotech enthusiasts — every founder can take away valuable insights on: 1) Asking for help and building teams with complementary skills — no founder succeeds alone. 2) Applying AI thoughtfully — it's a tool, not a magic wand. 3) Patience — ensure your foundation is strong before scaling. 4) Partnering with investors you trust and who align with your mission. 5) Setting a high bar for talent and culture — great people build great companies. 6) Communicating your differentiation — make your value clear to all stakeholders. Full Transcript: https://www.madrona.com/archon-unlocks-antibodies-with-ai-jamie-lazarovits Chapters: (00:00) Introduction (00:55) Jamie Lazarovitz's Journey from Deep Tech to Biotech (01:45) Early Ventures and Lessons Learned (05:03) The Motivation Behind Jamie's Biotech Passion (07:40) Joining the Institute for Protein Design - David Baker (09:40) Meeting Co-Founder George Ueda and the Birth of Archon (12:46) Revolutionary Protein Design at Archon: Antibody Cages (AbCs) (25:23) The Role of AI in Protein Design (27:50) Building a Successful Biotech Company (38:47) Future Prospects
NOW PLAYING
Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI
No transcript for this episode yet
Similar Episodes
Mar 23, 2026 ·48m
Mar 9, 2026 ·41m
Feb 9, 2026 ·41m
Feb 2, 2026 ·41m